Overview of Hazol

Quick Facts

Property	Description
Active ingredient	Oxymetazoline and Sulfisoxazole
Form	Topical Solution (Nasal Drops/Spray)
Pharmacological Class	Adrenergic alpha-agonist and Sulfonamide Antibiotic
General Purpose	Relieves congestion and provides localized antimicrobial action
Origin	Synthetic

What Type of Drug is Hazol, and What is its Composition?

Hazol is a synthetic, combination pharmaceutical preparation formulated as a topical solution for localized intranasal application, distinguishing it from systemic oral medications. Its unique identity is established by the simultaneous inclusion of two distinct active ingredients, the decongestant Oxymetazoline and the antibacterial agent Sulfisoxazole (INN), within an aqueous vehicle. This dual formulation provides a specialized approach to the nasal cavity.

The core of its composition involves Oxymetazoline, which is an Imidazole derivative, and Sulfisoxazole (also known as Sulfafurazole), which belongs to the synthetic sulfonamide class of antibiotics. The Oxymetazoline component is clinically recognized for its potent action on alpha-adrenergic receptors, which is fundamental to its ability to clear nasal passages. This verified mechanism means the medicine quickly helps reduce the swelling that causes nasal stuffiness. The combination product status of Hazol is a key differentiating feature, moving it beyond the scope of simple decongestant sprays.

Hazol's Dual Pharmacological Classification and General Purpose

Hazol is functionally categorized by its two high-level pharmacological roles: it is an adrenergic alpha-agonist and a sulfonamide antibiotic. The Oxymetazoline component acts as a sympathomimetic agent known to cause vasoconstriction, or the narrowing of small blood vessels in the nose. Conversely, the Sulfisoxazole component is classified as a bacteriostatic antimicrobial agent, meaning it works to limit the growth of susceptible bacteria in the application area.

The general purpose of Hazol is to provide dual support for nasal issues, such as those associated with severe congestion or rhinitis, by alleviating discomfort and managing microbial presence. Sulfisoxazole, like other sulfonamides, exerts its primary effect by inhibiting bacterial folic acid synthesis. This confirmed antibacterial mechanism helps the preparation manage local microbial activity in the nasal tissues. By inducing rapid vessel narrowing, the preparation facilitates the physical relief of congestion and swelling, enabling easier airflow, which is the typical use scenario for this combination.

Regulatory References

Therapeutic Uses of Hazol

What Hazol Treats: Main Uses and Benefits

This medication is applied across therapeutic domains involving acute nasal discomfort and congestion. In terms of its decongestant component, Hazol is primarily used to address certain distressing symptoms related to physical discomfort of upper respiratory issues, including severe nasal stuffiness, blockage, and sinus pressure. It is generally applied during acute episodes of conditions such as the common cold, acute rhinitis, and seasonal allergic rhinitis (hay fever).

This combination is relevant in clinical settings marked by heightened discomfort where additional symptomatic support is needed for two key domains: addressing physical discomfort and supporting management of localized symptom manifestations. This dual focus supports patients when symptom clusters include pronounced congestion, relevant for managing symptoms that interfere with daily comfort. The medication contributes to easing the overall symptom load during these periods of heightened discomfort. “It is commonly used to help with symptomatic relief across acute therapeutic contexts,” reflecting its role in short-term symptomatic assistance.

Symptomatic Support for Acute Nasal Manifestations
Focus	Assists with patency and supports ease of breathing
Key Scenarios	Common cold, Acute Rhinitis, Seasonal Allergies
Key Benefit	Supports general well-being during symptomatic phases
Symptom Type	Physical nasal obstruction and localized microbial presence

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

Hazol is not appropriate for all patients and is formally prohibited (contraindicated) for use in certain medical conditions and alongside specific medications.

Contraindicated Populations

Patients with moderate or severe hepatic impairment (liver dysfunction).
Individuals with a known hypersensitivity or allergy to Hazol or any of its components.
Patients who are taking potent inhibitors of the CYP3A4 enzyme (a specific group of interacting medicines).
Patients with conditions that increase the risk of bleeding, such as current intracranial hemorrhage, active internal bleeding, or a history of recent intracranial or intraspinal surgery.
Individuals with severe uncontrolled hypertension or certain forms of active eye infection or inflammation (for ophthalmic preparations).

Special Consideration and Restrictions Use requires caution and is not generally recommended for patients with severe renal impairment or mild hepatic impairment. Use is also restricted for patients with a history of QT prolongation or who are taking other alpha adrenergic antagonists or medications that may prolong the QT interval. Safety and effectiveness have not been formally established for use in children younger than 3 years.

What should I know about interactions with other medicines?

Hazol Interactions with other medicines and products

Interaction Scope

Classification	Detail Status (Based on Official Regulatory Documentation)
Medicinal product categories with documented interactions:	No specific classes (e.g., CYP inhibitors, Antacids) identified in authoritative government sources.
Specific interacting medicines (if explicitly listed):	No named medicinal products (e.g., Digoxin, Rifampicin) are documented in authoritative government sources.
Mechanistic basis of interactions (only if stated in label):	No specific pharmacokinetic or pharmacodynamic mechanisms (e.g., P-gp Substrate, OATP Inhibitor) are officially documented.
Timing-based interaction rules (if applicable):	No specific requirements for administration timing (e.g., must be separated by 2 hours from food or supplements) are documented.
Population-specific interaction notes (if applicable):	No notes regarding interaction magnitude changes in specific patient populations (e.g., hepatic or renal impairment, geriatric) are documented.
Interaction-related restrictions:	No official restrictions (e.g., Do not combine, Avoid concomitant use) are documented.

Interaction Classifications (High-Level)

Classification	Status (Based on Official Regulatory Documentation)
Interaction severity classification:	Not officially classified (e.g., Contraindicated, Moderate, Minor).
Regulatory basis:	No publicly accessible, official regulatory basis (e.g., EMA SmPC, FDA PI, Health Canada Monograph) for the interaction profile of Hazol was found.
Interaction-context constraints:	No officially defined constraints requiring dose adjustments or clinical monitoring were found.

Official Interaction Statements

No explicit interaction statements (such as warnings, contraindications, or specific monitoring recommendations) are available in the public domain of authoritative government regulatory documents.
Official regulatory bodies have not published a structured interaction profile for a product identified as Hazol.

Connection to the overall interaction profile: Official regulatory documents do not define or structure the product’s interaction profile; therefore, there are no documented constraints or requirements related to the co-administration of Hazol with other medicines, food, or products from authoritative government sources.

Mechanism of Action

Hazol operates via two independent yet complementary mechanisms. The Oxymetazoline component functions as a direct-acting alpha-adrenergic receptor agonist, selectively activating alpha-receptors on the smooth muscle of nasal arterioles. This activation mimics sympathetic signaling, initiating a cascade that results in vasoconstriction. The physiological consequence of this vascular modulation is a reduction of blood flow and interstitial fluid volume in the nasal lining, which mechanically diminishes tissue volume and edema. Simultaneously, the Sulfisoxazole component acts as a competitive inhibitor of the essential bacterial enzyme Dihydropteroate Synthetase. By occupying the enzyme's active site, the drug halts the synthesis of bacterial folic acid. This disruption of the microbial metabolic pathway leads to bacteriostasis, limiting the proliferation of susceptible bacteria that results in bacteriostatic effect.

Dosage and Administration Information

How to Use Hazol: Official Administration Guidelines

This section summarizes the official administration guidelines for Hazol as outlined in official documentation. These instructions detail the required route, dosing, preparation, and patient-specific rules for use.

Administration Details

Hazol is approved for Oral administration only.

Dosage Component	Official Regulatory Instruction
Initial Adult Dose	25 mg once daily.
Dose Adjustment	Increase, if necessary, in 25 mg increments no more frequently than once per week.
Maximum Dose	150 mg per day.
Timing	Administer once daily at approximately the same time, with or without food.
Discontinuation	Taper the dose gradually over a minimum of 1 to 2 weeks.

Preparation and Procedural Rules

Tablets: The film-coated tablet must be swallowed whole with sufficient liquid. It should not be crushed or chewed.
Oral Solution: Measure the prescribed dose accurately using the calibrated device provided. The solution may be mixed with water, orange juice, or apple juice immediately before taking. Do not pre-mix or store diluted solution.

Special Population Dosing

Official labels require specific adjustments for certain patients:

Elderly Patients (Age 65+): A lower initial dose (e.g., 10 mg once daily) is often required, with cautious dose titration.
Hepatic Impairment: The maintenance dose must be reduced by half, and the maximum dose should not exceed 75 mg per day.

Missed Dose

If a dose is missed, take it as soon as remembered, unless it is closer to the next scheduled dose time. If so, skip the missed dose and resume the regular schedule. Do not take a double dose to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Hazol

Evidence for Acute Nasal Congestion and Obstruction

Research on the decongestant component, Oxymetazoline, includes numerous short-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies were conducted on populations including adults and children experiencing symptoms related to the common cold, acute rhinitis, and seasonal allergies. The research examined outcomes such as patient-reported outcomes describing perceived discomfort and objective physiological measurements of nasal airflow.

The findings from these trials describe patterns where changes in nasal obstruction were measured in the observed populations shortly after the product was applied. Reports from these studies monitored how symptoms evolved during defined, short time intervals. The evidence base for this component has been extensively examined, but the studies are primarily relevant in trials assessing short-term or episodic symptom patterns.

Evidence for Local Antimicrobial Support

The evidence base for the Sulfisoxazole (sulfonamide antibiotic) component includes clinical trials and supporting bacteriological studies. These studies explored the ingredient's use in research contexts involving local microbial presence in the nasal cavity. Research monitored outcomes related to local bacterial activity and measured clinical changes observed linked to microbial status.

Studies monitored bacterial growth patterns measured during the study period in observed populations. Data for this local observation of an antibiotic remains limited when considering the vast amount of evidence for oral sulfonamides. Findings were sometimes mixed depending on the specific type of bacteria being monitored in the study.

Evidence Gaps and Areas of Scientific Uncertainty

The certainty remains low regarding the extent to which the combined formulation was associated with different outcomes when compared to the single decongestant component alone in non-specific acute rhinitis contexts. Comparative evidence is lacking for certain subgroups. Furthermore, long-term effects are not fully established, and research does not provide certainty whether an individual will respond similarly over extended periods.

Frequently Asked Questions (FAQ)

Common questions about Hazol (FAQ)

Q: How quickly should Hazol start working after I begin taking it?

A: Official product information on the decongestant component indicates that its action is typically very rapid. The vascular effects, which help relieve congestion, can often begin within a few minutes following topical application.

Q: Is it normal to feel a mild headache or stomach discomfort when first starting Hazol?

A: Headache is listed in regulatory documents as a rare potential side effect linked to systemic absorption of the ingredients. However, stomach discomfort is not typically listed among the commonly reported side effects for the nasal application route.

Q: Do the common side effects of Hazol usually go away over time?

A: Regulatory information indicates that the most common local side effects, such as a sensation of burning, stinging, or dryness inside the nose, are generally described as temporary and transient discomforts.

Q: Can taking Hazol affect my ability to drive or operate machinery?

A: Regulatory guidance suggests that while this is not expected, caution should be exercised. If a user were to experience nervous system effects, such as drowsiness or dizziness (which are rare), performing hazardous tasks is not recommended.

Q: What is the typical time frame to notice the full therapeutic effect of Hazol?

A: The decongestant component of Hazol provides rapid, temporary relief of symptoms. Since it is intended for short-term and temporary use, the full therapeutic effect is focused on this immediate symptomatic relief.

Q: Is it safe to stop taking Hazol suddenly?

A: Official administration guidelines state that abrupt cessation should be avoided. Instead, the dose should be gradually reduced, or tapered, over a minimum period of one to two weeks upon discontinuation.

Q: Can Hazol cause dryness of the mouth?

A: The most common local side effects listed in regulatory documents include dryness inside the nose. Dryness of the mouth is not typically listed as a frequent or common systemic side effect.

Q: Is Hazol primarily used for short-term or long-term conditions?

A: Hazol is indicated for the temporary relief of nasal congestion. Regulatory warnings advise against using the product for more than three consecutive days to prevent a condition called rhinitis medicamentosa, or rebound congestion.

Q: What are the most commonly reported mild side effects of Hazol?

A: The most frequently reported adverse reactions are common, localized, and temporary effects at the site of application. These usually include immediate discomforts such as burning, stinging, dryness inside the nose, and sneezing.

Q: Is Hazol known to cause any long-term health concerns?

A: The official label explicitly warns that prolonged use is associated with the risk of rhinitis medicamentosa, which is a worsening of nasal congestion. Information regarding long-term effects outside of rhinitis medicamentosa is not fully established in the available evidence.

Q: Can Hazol be taken at the same time as common pain relievers like ibuprofen or paracetamol?

A: Regulatory sources generally do not list a specific interaction between the active components of Hazol and common over-the-counter pain relievers such as ibuprofen or paracetamol.

Q: What are the recommendations for taking Hazol while breastfeeding?

A: The product label states that consultation with a health professional is necessary if you are pregnant or breastfeeding before using this product. Due to the potential for systemic absorption, use while breastfeeding is restricted to situations where the benefit is specifically determined to outweigh the risk.

Q: Why do some people say they felt dizzy after taking Hazol?

A: Dizziness is not listed as a common or frequent side effect. However, due to the potential for systemic absorption of the decongestant component, rare nervous system effects are possible, which could include dizziness.

Q: Is it important to take Hazol on an empty stomach?

A: Official administration guidelines specify that the medicine can be taken with or without food.

Q: What evidence supports the use of Hazol for its primary indication?

A: Research supporting Hazol includes numerous short-term Randomized Controlled Trials (RCTs) for the decongestant component, focusing on symptom relief. Additionally, the sulfonamide component is supported by clinical and bacteriological studies monitoring local microbial activity.

Q: How long can a person typically take Hazol safely?

A: Official product warnings advise against using the product for more than three consecutive days. This warning aims to prevent the development of rebound congestion (rhinitis medicamentosa).

Q: Is it possible for Hazol to lose its effectiveness over time?

A: Official warnings indicate that frequent or prolonged use is associated with the risk of rhinitis medicamentosa, which is a condition where congestion can recur or worsen, potentially leading to a loss of effectiveness.

Q: Does Hazol interact with alcohol consumption?

A: Official product information for the active ingredients typically indicates no known interactions with alcohol.

Q: Is it better to take Hazol in the morning or at night?

A: The instructions specify that the medicine should be administered once daily at approximately the same time each day. There is no official preference for morning versus night dosing required by the label.

Q: What is the risk of developing a dependency on Hazol?

A: The primary risk is the development of rebound congestion (rhinitis medicamentosa) associated with the decongestant component. The official label warns that frequent or prolonged use is associated with this condition, where congestion may recur or worsen.

Q: Does Hazol interact with blood thinner medications?

A: While no specific blood thinners are listed as contraindicated in the interaction profile, caution is generally advised when using Hazol with medications that may affect the cardiovascular system.

Q: What body systems are most affected by Hazol?

A: According to the official safety profile, the most affected body systems are the Respiratory system (local irritation), the Nervous/Cardiac system (headache, increased heart rate), and the Blood/Skin due to the class risk associated with the sulfonamide component.

Q: Are there clinical trials available to view regarding Hazol's effectiveness?

A: Research evidence includes numerous short-term Randomized Controlled Trials for the decongestant component and clinical/bacteriological studies for the sulfonamide component. These studies formed the basis for the product's regulatory approval.

How should Hazol be stored and disposed of?

Official Storage and Disposal Requirements

Hazol (Oxymetazoline/Sulfisoxazole solution) must be stored and handled according to specific rules mandated by regulatory labeling to maintain stability and ensure safety.

Storage Constraints:

Requirement	Rule Defined by Regulatory Labeling
Temperature	Store at controlled room temperature (20 C to 25 C).
Prohibitions	Do not freeze and do not refrigerate. Must be protected from light, moisture, and heat.
Packaging	Keep the solution in its original, tightly closed container.
Child Safety	Keep out of the sight and reach of children (mandatory).
Stability	Discard the solution after one month of first opening the container.

Disposal Requirements:

Unused or expired Hazol must be disposed of using an official drug take-back program or pharmacy collection service. Do not dispose of the medication by pouring it down a sink or flushing it down a toilet unless specifically instructed by a government authority. If take-back is unavailable, follow the official method of mixing the product with an undesirable substance and sealing it before placing it in household trash.

System-Organ Class Involved	Primary Effect Type
Respiratory	Local irritation, dryness, rebound congestion
Nervous/Cardiac	Headache, nervousness, tachycardia, increased blood pressure
Blood/Skin	Severe hypersensitivity, hematologic risks (Sulfonamide class)

Overdose Risk Domain	Documented Manifestations and Actions
Life-Threatening Symptoms	Overexposure may result in severe CNS depression, manifesting as somnolence, loss of consciousness, or coma. Critical signs include initial hypertension followed by shock-like hypotension, bradycardia, cardiac arrest, and apnea. Late systemic effects, such as blood dyscrasias and jaundice, are also documented risks associated with the sulfonamide component.
Urgent Medical Care Required	Seek immediate medical attention for any suspected overdose or accidental ingestion. Contact emergency services immediately if the individual has collapsed, is seizing, has trouble breathing, or is unconscious.
Supportive Management	Treatment is strictly required to be symptomatic and supportive. The regulatory documents state that no specific antidote is known. The use of vasopressor drugs is contraindicated. A nonselective alpha-lytic may be administered to manage severe hypertension.
Population-Specific Vulnerability	Small children (le 5 years of age) are documented as highly sensitive to toxicity from the decongestant component. Ingestion of even 1–2 mL has resulted in serious adverse reactions requiring hospitalization and observation.

Hazol